AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 161 min read$UTHR

MAHON PAUL A sold $4.5M of UTHR

MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $544.30 ($541.64–$546.56, $4.52M total) across 6 trades on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAHON PAUL A
Published Oct 16, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The $4.5 M sale represents a notable but not massive stake reduction, likely prompting short‑term price softness.

02

Market read

Insider sell signals possible caution; traders may watch for price reaction and any accompanying news.

03

What to watch

Potential upcoming clinical data or financing events could offset the sell‑off pressure.

Relevance 5/10Novelty 7/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions; such disclosures are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

EVP & General Counsel Paul Mahon sold $4.5M of United Therapeutics shares via a 10b5‑1 plan on 2026‑10‑15.

Expected impact

likely downward pressure as the market prices the insider sell.

Evidence & confidence

Form 4 filing is a primary source; $4.5 M is material for a mid‑cap biotech, and the sale was executed through a pre‑arranged plan, suggesting a neutral to slightly bearish impact.

Market effects

Sector

May prompt scrutiny of insider activity in biotech sector but no broader sector shift.

Regional

Limited to U.S. markets; no regional ripple.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale was pre‑arranged under a 10b5‑1 plan, so it may not reflect new negative information.

Key entities

  • company
    United Therapeutics Corp

    Biopharmaceutical company developing therapies for pulmonary arterial hypertension and other diseases.

  • person
    Paul Mahon

    Executive Vice President & General Counsel of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min